Literature DB >> 26113598

Vasotropic light-chain amyloidosis and ischaemic cholangiopathy.

Emma L Johnston1, Mark Wilkinson1, A S Knisely2.   

Abstract

A 75-year-old woman was incidentally found to have deranged liver function tests (LFTs). She was well, apart from 2 years of dyspnoea. Investigations had revealed atrial fibrillation and a right pleural effusion, without identified aetiology. On examination, the only finding was a palpable liver edge. Initial blood and ultrasound screening suggested no cause. The patient underwent liver biopsy. Microscopy showed κ-immunoglobulin light chains deposited exclusively in portal tracts, within blood vessel and bile duct walls. This pattern, although unusual, raised the possibility of κ-light chain disease. Serum electrophoresis was normal, as were serum immunoglobulin values. Serum concentrations of κ-light chains were elevated and microscopy of aspirated bone marrow found light-chain deposits with 10% plasmacytosis. Serum amyloid P (SAP) scintigraphy demonstrated splenic uptake. Myeloma, κ-light chain, with light-chain amyloidosis was diagnosed. The patient has responded well to cyclophosphamide, bortazomib and dexamethasone chemotherapy, and her LFTs are now nearly normal. 2015 BMJ Publishing Group Ltd.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26113598      PMCID: PMC4488634          DOI: 10.1136/bcr-2015-210883

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  5 in total

Review 1.  Amyloidosis: pathogenesis and new therapeutic options.

Authors:  Giampaolo Merlini; David C Seldin; Morie A Gertz
Journal:  J Clin Oncol       Date:  2011-04-11       Impact factor: 44.544

Review 2.  Gastrointestinal manifestations of amyloidosis.

Authors:  Ellen C Ebert; Michael Nagar
Journal:  Am J Gastroenterol       Date:  2007-12-12       Impact factor: 10.864

3.  Development of rapid light-chain deposition disease in hepatic arteries with severe ischemic cholangitis in a multiple myeloma patient treated with melphalan, prednisone and lenalidomide.

Authors:  Katja C Weisel; Michael Böckeler; Leonardo Bianchi; Luigi M Terracciano; Frank Mayer; Lothar Kanz
Journal:  Int J Hematol       Date:  2008-12-20       Impact factor: 2.490

Review 4.  Primary amyloidosis and severe intrahepatic cholestatic jaundice.

Authors:  R A Peters; G Koukoulis; A Gimson; B Portmann; D Westaby; R Williams
Journal:  Gut       Date:  1994-09       Impact factor: 23.059

5.  Hepatic amyloidosis. A histopathologic analysis of primary (AL) and secondary (AA) forms.

Authors:  S Chopra; A Rubinow; R S Koff; A S Cohen
Journal:  Am J Pathol       Date:  1984-05       Impact factor: 4.307

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.